Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data XTL BIOPHARMACEUTICALS LTD files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2015
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2024
FY2024
Revenue
0.45
Cost of revenue
0.45
Gross profit
0
Research and development
0.58
0.44
0.04
0.04
0.04
0.04
0.03
0.03
0.03
0.1
General and administrative
0.76
0.81
0.91
Operating income
-3.61
-2.56
-1.25
-0.79
-0.84
-0.95
-1.03
-0.88
-0.77
-2.17
Interest expense
0.02
0.01
0.34
0.04
0.6
2.19
0.02
1.56
Interest income
0
0.02
0.8
3.81
0.68
0.18
1.49
1.09
0.04
1.13
Pre-tax income
-1.35
-1.78
-1.16
Income tax
-0.13
Income from continuing operations
-3.62
-2.55
-0.78
Net income to minority interests
-4.31
-2.55
-0.78
2.99
-1.35
Net income
0
-2.55
-0.78
3.63
-0.76
-2.95
0.44
-1.35
-1.78
-1.03
EBITDA
-3.6
-2.56
-1.25
EPS, basic
-0.01
-0.00
-0.00
0.00
-0.00
-0.01
0.00
-0.00
-0.00
-0.00
EPS, diluted
-0.01
-0.00
-0.00
0.00
-0.00
-0.01
0.00
-0.00
-0.00
-0.00
Balance sheet
FY2015
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2024
FY2024
Cash and equivalents
3.82
2.02
3.29
3.26
4.46
3.63
2.97
2.09
1.4
0.37
Short-term investments
2.27
2.41
3.16
1.63
Total current assets
2.75
6.21
8.2
6.83
6.12
6.24
3.81
2.05
1.34
Property, plant and equipment
0.01
0.19
Goodwill
3.19
Intangible assets
1.04
0.25
0.38
0.38
0.38
0.38
0.38
0.38
0.38
3.82
Total assets
3.02
6.59
8.58
7.21
6.5
6.62
4.19
2.43
8.55
Short-term debt
0.14
Total current liabilities
0.33
0.3
0.21
2.21
Total liabilities
0.33
2.97
1.3
0.7
2.89
1.29
0.19
0.21
3.12
Total debt
0.14
Paid-in capital
151
146
148
146
146
Retained earnings
-155
-156
-153
-153
-156
-155
-156
-158
-159
Total equity
4.89
2.69
3.62
7.27
6.52
3.61
5.33
4
2.22
5.44
Total liabilities and equity
3.02
6.59
8.58
7.21
6.5
6.62
4.19
2.43
8.55
Cash flow statement
FY2015
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2024
FY2024
Net income
-4.31
-2.55
-0.78
3.63
-0.76
-2.95
0.44
-1.35
-1.78
-1.03
Depreciation and amortization
0.01
0
0
Cash from operations
-1.86
-1.73
-1.13
-0.82
-0.91
-0.85
-1.05
-0.9
-0.71
-1.62
Capital expenditures
-0
-0
-0
-0
-0.05
Cash from investing
-0.11
-0.07
-2.5
0.78
2.11
0.03
0.01
0.04
0.04
-0.84
Debt repaid
-0.01
Cash from financing
3.58
4.89
0.39
1.45
Exchange rate effect
-0
-0
0
-0
-0.01
-0.01
-0.01
-0.03
-0.02
Net change in cash
1.2
-0.82
-0.66
-0.87
-0.67
-1.02
Free cash flow
-1.86
-1.73
-0.91
-0.85
-1.67
Key metrics
Worked out from the statements above. Latest values use fiscal 2024. Valuation uses the share price of $2.20 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
0.7%
Gross profit / revenue.
Operating margin
-481.6%
Operating income / revenue.
Pre-tax margin
-256.5%
Pre-tax income / revenue.
Net margin
-227.7%
Net income / revenue.
FCF margin
-370.7%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-358.8%
Cash from operations / revenue.
Return on assets (ROA)
-18.7%
Net income / average total assets.
R&D / revenue
21.7%
Research and development expense / revenue.
Capex / revenue
12.0%
Capital expenditures / revenue.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
252.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
8.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
3.5%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.61x
Current assets / current liabilities.
Quick ratio
0.17x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.17x
(Cash + short-term investments) / current liabilities.
Debt / assets
1.6%
Total debt / total assets.
Liabilities / assets
36.4%
Total liabilities / total assets.
Net debt
-$233.0K
Total debt - cash - short-term investments. Negative means more cash than debt.
Working capital
-$867.0K
Current assets - current liabilities.
Goodwill and intangibles / assets
82.0%
(Goodwill + intangible assets) / total assets.
Efficiency
Metric
Value
How it is calculated
Asset turnover
0.08x
Revenue / average total assets.
Fixed asset turnover
2.41x
Revenue / average property, plant and equipment.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.00
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$0.00
Net income per basic share, as reported (split-adjusted).
Valuation
Metric
Value
How it is calculated
Market cap
$5.4M
Share price x shares outstanding.
Enterprise value
$5.2M
Market cap + total debt - cash - short-term investments.
P/S
12.0x
Market cap / revenue.
EV/Sales
11.5x
Enterprise value / revenue.
FCF yield
-30.9%
Free cash flow / market cap.
Earnings yield
-19.0%
Net income / market cap (the inverse of P/E).
What was XTL BIOPHARMACEUTICALS LTD's revenue in fiscal 2024?
XTL BIOPHARMACEUTICALS LTD reported revenue of $451.0K for fiscal 2024.
Was XTL BIOPHARMACEUTICALS LTD profitable in fiscal 2024?
No. It reported a net loss of $1.0M.
How much free cash flow did XTL BIOPHARMACEUTICALS LTD generate in fiscal 2024?
Cash from operations of $1.6M minus capital expenditures of $54.0K left free cash flow of -$1.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.